Cargando…

Interleukin 34: a new modulator of human and experimental inflammatory bowel disease

IBD (inflammatory bowel disease), where CD (Crohn's disease) and UC (ulcerative colitis) represent the two main forms, are chronic inflammatory conditions of the intestine. Macrophages play a central role in IBD pathogenesis and are regulated by major differentiation factors such as CSF-1 (colo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwicker, Stephanie, Martinez, Gisele L., Bosma, Madeleen, Gerling, Marco, Clark, Reuben, Majster, Mirjam, Söderman, Jan, Almer, Sven, Boström, Elisabeth A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557398/ https://www.ncbi.nlm.nih.gov/pubmed/25896238 http://dx.doi.org/10.1042/CS20150176

Ejemplares similares

Receptor-Type Protein-Tyrosine Phosphatase ζ and Colony Stimulating Factor-1 Receptor in the Intestine: Cellular Expression and Cytokine- and Chemokine Responses by Interleukin-34 and Colony Stimulating Factor-1
por: Zwicker, Stephanie, et al.
Publicado: (2016)

FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice
por: Bosma, Madeleen, et al.
Publicado: (2016)

Salivary and Serum Inflammatory Profiles Reflect Different Aspects of Inflammatory Bowel Disease Activity
por: Majster, Mirjam, et al.
Publicado: (2020)

Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study
por: Zwicker, Stephanie, et al.
Publicado: (2017)

Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease
por: Norén, Elisabeth, et al.
Publicado: (2017)

Increased Eotaxin and MCP-1 Levels in Serum from Individuals with Periodontitis and in Human Gingival Fibroblasts Exposed to Pro-Inflammatory Cytokines
por: Boström, Elisabeth A., et al.
Publicado: (2015)

Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders †
por: Haglund, Sofie, et al.
Publicado: (2023)

Gene Expression-Genotype Analysis Implicates GSDMA, GSDMB, and LRRC3C as Contributors to Inflammatory Bowel Disease Susceptibility
por: Söderman, Jan, et al.
Publicado: (2015)

S100A12 Expression Is Modulated During Monocyte Differentiation and Reflects Periodontitis Severity
por: Lira-Junior, Ronaldo, et al.
Publicado: (2020)

Gene Expression and Thiopurine Metabolite Profiling in Inflammatory Bowel Disease – Novel Clues to Drug Targets and Disease Mechanisms?
por: Haglund, Sofie, et al.
Publicado: (2013)

Genetic Variation and Gene Expression Levels of Tight Junction Genes Indicates Relationships Between PTEN as well as MAGI1 and Microscopic Colitis
por: Norén, Elisabeth, et al.
Publicado: (2017)

Inverse and Concordant Mucosal Pathway Gene Expressions in Inflamed and Non-Inflamed Ulcerative Colitis Patients: Potential Relevance to Aetiology and Pathogenesis
por: Söderman, Jan, et al.
Publicado: (2022)

Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells – Effects on gene expression levels and thiopurine metabolism
por: Haglund, Sofie, et al.
Publicado: (2017)

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
por: Visuri, Isabella, et al.
Publicado: (2023)

Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer
por: Wuensch, Tilo, et al.
Publicado: (2019)

Erratum to “Expression Analysis of Fibronectin Type III Domain-Containing (FNDC) Genes in Inflammatory Bowel Disease and Colorectal Cancer”
por: Wuensch, Tilo, et al.
Publicado: (2020)

Role of CD34 in inflammatory bowel disease
por: Li, Zhiyuan, et al.
Publicado: (2023)

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

The Newly Discovered Cytokine IL-34 Is Expressed in Gingival Fibroblasts, Shows Enhanced Expression by Pro-Inflammatory Cytokines, and Stimulates Osteoclast Differentiation
por: Boström, Elisabeth A., et al.
Publicado: (2013)

Periodontitis is associated to increased systemic inflammation in postmyocardial infarction patients
por: Lira-Junior, Ronaldo, et al.
Publicado: (2021)

Expression of Interleukin-26 is upregulated in inflammatory bowel disease
por: Fujii, Makoto, et al.
Publicado: (2017)

The anti-inflammatory and protective role of interleukin-38 in inflammatory bowel disease
por: Ohno, Masashi, et al.
Publicado: (2022)

Screening for thyroid dysfunction with free T4 instead of thyroid stimulating hormone (TSH) improves efficiency in older adults in primary care
por: Bosma, Madeleen, et al.
Publicado: (2022)

Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study
por: Oxelmark, Lena, et al.
Publicado: (2016)

Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease
por: Krawiec, Paulina, et al.
Publicado: (2020)

Role of Interleukin-34 in Cancer
por: Franzè, Eleonora, et al.
Publicado: (2020)

Interleukin-24 regulates mucosal remodeling in inflammatory bowel diseases
por: Ónody, Anna, et al.
Publicado: (2021)

Experimental Models of Inflammatory Bowel Diseases
por: Kiesler, Patricia, et al.
Publicado: (2015)

Interleukin 10 and interleukin 10 receptor in paediatric inflammatory bowel disease: from bench to bedside lesson
por: Krawiec, Paulina, et al.
Publicado: (2021)

Interleukin-33 and Inflammatory Bowel Diseases: Lessons from Human Studies
por: Nunes, Tiago, et al.
Publicado: (2014)

Interleukin-1 associations in inflammatory bowel disease and the enteropathic seronegative spondylarthritis
por: Vounotrypidis, Periklis, et al.
Publicado: (2013)

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors
por: Fieldhouse, Keira A, et al.
Publicado: (2020)

Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention
por: Sewell, Gavin W, et al.
Publicado: (2022)

Leukocyte migration in experimental inflammatory bowel disease
por: Van Rees, E. P., et al.
Publicado: (1997)

Interleukin-10: An Anti-Inflammatory Marker To Target Atherosclerotic Lesions via PEGylated Liposomes
por: Almer, Gunter, et al.
Publicado: (2012)

Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease
por: Seo, Dong Hyuk, et al.
Publicado: (2017)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

The Role of T Follicular Helper Cells and Interleukin-21 in the Pathogenesis of Inflammatory Bowel Disease
por: Sun, Lulu, et al.
Publicado: (2021)

Interleukin-26 Expression in Inflammatory Bowel Disease and Its Immunoregulatory Effects on Macrophages
por: Song, Dongjuan, et al.
Publicado: (2022)

Insights into the molecular mechanisms and therapeutic implications of interleukin-6 for inflammatory bowel disease
por: Tie, Yizhe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pjarkk9sfjh0dcb3v6lqvb436s